Your browser doesn't support javascript.
loading
Impact of Bone Marrow miR-21 Expression on Acute Myeloid Leukemia T Lymphocyte Fragility and Dysfunction.
Moussa Agha, Douâa; Rouas, Redouane; Najar, Mehdi; Bouhtit, Fatima; Fayyad-Kazan, Hussein; Lagneaux, Laurence; Bron, Dominique; Meuleman, Nathalie; Lewalle, Philippe; Merimi, Makram.
Afiliação
  • Moussa Agha D; Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium.
  • Rouas R; Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium.
  • Najar M; Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM) and Department of Medicine, University of Montreal, Montreal, QC H2X 0A9, Canada.
  • Bouhtit F; Genetics and Immune Cell Therapy Unit, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.
  • Fayyad-Kazan H; Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium.
  • Lagneaux L; Genetics and Immune Cell Therapy Unit, Faculty of Sciences, University Mohammed Premier, Oujda 60000, Morocco.
  • Bron D; Laboratory of Cancer Biology and Molecular Immunology, Faculty of Sciences I, Lebanese University, Hadath 90656, Lebanon.
  • Meuleman N; Laboratory of Clinical Cell Therapy, Jules Bordet Institute, Université Libre de Bruxelles, 1070 Bruxelles, Belgium.
  • Lewalle P; Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium.
  • Merimi M; Laboratory of Experimental Hematology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Bruxelles, Belgium.
Cells ; 9(9)2020 09 08.
Article em En | MEDLINE | ID: mdl-32911844
BACKGROUND: Acute myeloid leukemia (AML) is a hematopoietic malignancy in which antitumor immunity is impaired. The therapeutic management of AML requires understanding the mechanisms involved in the fragility and immune dysfunction of AML T lymphocytes. METHODS: In this study, T lymphocytes from healthy donors (HD) and AML patients were used. Extracellular vesicles (EVs) from leukemic cells were screened for their microRNA content and impact on T lymphocytes. Flow cytometry, transcriptomic as well as lentiviral transduction techniques were used to carry out the research. RESULTS: We observed increased cell death of T lymphocytes from AML patients. EVs from leukemia myeloid cell lines harbored several miRNAs, including miR-21, and were able to induce T lymphocyte death. Compared to that in HD, miR-21 was overexpressed in both the bone marrow fluid and infiltrating T lymphocytes of AML patients. MiR-21 induces T lymphocyte cell death by upregulating proapoptotic gene expression. It also increases the immunosuppressive profile of T lymphocytes by upregulating the IL13, IL4, IL10, and FoxP3 genes. CONCLUSIONS: Our results demonstrate that miR-21 plays a significant role in AML T lymphocyte dysfunction and apoptosis. Targeting miR-21 may be a novel approach to restore the efficacy of the immune response against AML.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medula Óssea / Linfócitos T / Leucemia Mieloide Aguda / MicroRNAs Tipo de estudo: Observational_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Cells Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medula Óssea / Linfócitos T / Leucemia Mieloide Aguda / MicroRNAs Tipo de estudo: Observational_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Cells Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Bélgica